v3.26.3
Unaudited Condensed Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended 9 Months Ended 15 Months Ended
Sep. 30, 2026
Mar. 31, 2026
Sep. 30, 2025
Mar. 31, 2025
Sep. 30, 2026
Sep. 30, 2025
Sep. 30, 2025
Cash flows from operating activities              
Net loss $ (13,063,478) $ (7,714,951) $ (3,244,834) $ (8,285,791) $ (24,196,214) $ (13,158,560)  
Adjustments to reconcile net loss to net cash flows from operating activities:              
Share-based compensation expense         13,933,089 966,359  
Depreciation expense 0   0   444,884 127,539  
Change in fair value of SAFE Notes 0   0   0 7,725,000  
Gain on extinguishment of SAFE Notes 0   0   0 (853,000)  
Changes in operating assets and liabilities:              
Accounts receivable, net         (8,516,912) (447,591)  
Contract assets         (1,152,510) (286,010)  
Prepaid and other current assets         (2,774,217) (31,250)  
Accounts payable         (1,688,288) 308,988  
Accrued expenses and other liabilities         1,793,730 118,065  
Deferred revenue         5,589,794 126,118  
Net cash used in operating activities         (16,566,644) (5,404,342)  
Cash flows from investing activities              
Purchases of property and equipment         (32,205,821) (4,941,689)  
Contributions to equity method investment         (1,418,326) 0  
Net cash used in investing activities         (33,624,147) (4,941,689)  
Cash flows from financing activities              
Proceeds from IPO, net of underwriting discounts and commissions         141,000,000 0  
Payment of offering costs         (3,591,837) 0  
Proceeds from repayment of promissory notes for restricted stock purchases         2,762,094 0  
Proceeds from the exercise of stock options         62,361 0  
Proceeds from issuance of redeemable preferred shares         70,000,020 77,945,676  
Net cash provided by financing activities         210,232,638 77,945,676  
Net increase in cash and cash equivalents         160,041,847 67,599,645  
Cash and cash equivalents at beginning of period   $ 63,101,704   $ 1,619,817 63,101,704 1,619,817  
Cash and cash equivalents at end of period $ 223,143,551   $ 69,219,462   223,143,551 69,219,462 $ 69,219,462
Supplemental disclosure of cash flow information:              
Cash paid for interest         0 0  
Cash paid for income taxes         0 0 $ 0
Supplemental disclosure of non-cash investing and financing activities:              
Conversion of redeemable preferred stock to Class A common stock         214,999,997 0  
Reclassification of deferred transaction costs to additional paid-in capital         3,290,415 0  
Conversion of SAFE Notes into Series Seed-1 Preferred stock         0 32,500,000  
Reclassification of SAFE Notes fair value to mezzanine equity upon conversion         0 32,500,000  
Extinguishment of SAFE Notes (reduction of SAFE Notes liability)         0 1,000,000  
Reclassification of short-term cash advances to Series Seed preferred stock         0 2,494,833  
Investment in joint venture included in accounts payable         66,667 0  
Property and equipment purchases included in accounts payable and accrued and other liabilities         3,358,157 1,209,738  
Share-based compensation capitalized to property and equipment         159,159 0  
Vesting Of Early Exercised Restricted Stock         $ 294,476 $ 0